Health
Experts Doubt Kennedy’s Timetable for Finding the Cause of Autism
Robert F. Kennedy Jr., the nation’s health secretary, pledged on Thursday to seek out experts globally to discover the reasons for the increasing rates of autism in the United States.
“We’ve launched a massive testing and research effort that’s going to involve hundreds of scientists from around the world,” Mr. Kennedy announced at a cabinet meeting held by President Trump. “By September, we will know what has caused the autism epidemic and we’ll be able to eliminate those exposures.”
“There will be no bigger news conference than that,” Mr. Trump replied.
But scientists who have worked for decades to find a cause greeted Mr. Kennedy’s predicted timeline with skepticism.
They said that a single answer would be hard to identify in a field of possible contributors including pesticides, air pollution and maternal diabetes.
Dr. Philip Landrigan, a pediatrician and expert on environmental toxins, pointed to the current mass layoffs and cutbacks for research at Mr. Kennedy’s Department of Health and Human Services as one reason for doubting such quick progress.
“Given that a great deal of research on autism and other pediatric diseases in hospitals and medical schools is currently coming to a halt because of federal funding cuts from H.H.S.,” he said, “it is very difficult for me to imagine what profound scientific breakthrough could be achieved between now and September.”
Mr. Kennedy’s office did not offer many details on the plan. Later on Thursday, Mr. Kennedy revealed a few more clues, saying that the National Institutes of Health would lead the effort.
He said the Centers for Disease Control and Prevention would soon release data showing that the autism diagnoses had now increased to one of every 31 children. Many scientists and doctors attributed the rise in autism rates over the last several decades in part to growing awareness of the disorder and to expanded diagnoses along a spectrum.
“We are launching requests to scientists from all over the country and all over the world,” Mr. Kennedy said in an interview on Fox News. “Everything is on the table: our food system, our water, our air, different ways of parenting, all the kind of changes that may have triggered this epidemic.”
In the interview, Mr. Kennedy also said an important part of the effort would be to compare autism rates in vaccinated and unvaccinated children. It’s an angle that many scientists dismiss, saying that parents who vaccinate their children are also more likely to get a diagnosis, given higher rates of interaction with health providers.
Many scientists who have observed Mr. Kennedy’s dogged opposition to many vaccines over two decades — and his frequent attempts to tie autism to vaccines — have dismissed his claims, citing the scientific consensus that debunked any such link. Scrutiny of his pledges to begin “gold standard” research only heightened in recent weeks when David Geier, a largely discredited researcher, was hired at H.H.S. to study any potential link between vaccines and autism.
Irva Hertz-Picciotto, director of environmental epidemiology of neurodevelopment at the University of California at Davis MIND Institute, said she had been seeking a cause for autism for 20 years.
It’s an exciting time for the field, she said, with multiple studies beginning to point to factors that could play a role. Among the possible links are pesticide exposure through food or nearby agricultural fields; workplace exposures to solvents; fevers or infections during pregnancy; maternal diabetes; and exposure to chemicals in plastics called phthalates or to PFAS, known as “forever chemicals” for their tendency to persist in the environment.
Some studies have found that the effect of environmental exposures can vary based on a person’s genes, “emphasizing the complexity of this syndrome.” Dr. Hertz-Picciotto said it was challenging to get funding for clinical studies that could shed light on a cause of autism, but new research could help advance the field. Those studies, though, could take years.
That all of the research could be sorted out by September, she said, was “ludicrous.”
Dr. Alice Kuo, the chief of pediatric medicine who cares for children and adults with autism at the University of California, Los Angeles, said she was involved in a yearslong project by the National Institutes of Health called the National Children’s Study. It followed thousands of children and parents and elicited information, including the possible causes of autism. The study was costly and ended far earlier than planned, Dr. Kuo said.
She said an effort to do something as rigorous would take months to plan and design — and years to arrive at an answer.
In a social media post on Thursday, Mr. Kennedy recognized the assistance of the president and the Make America Healthy Again Commission — a subgroup of the cabinet that includes Linda McMahon, the education secretary, and Russell Vought, director of the Office of Management and Budget. Like Mr. Kennedy, they are not doctors or scientists.
“Thanks to your MAHA Commission, we’ll soon identify the root causes of the autism epidemic,” Mr. Kennedy wrote in a social media post.
Created by an executive order in February, the commission is charged with assessing in 100 days the threat to children of food ingredients, chemicals, medications and other exposures. Within 180 days, the commission is expected to submit a strategy to the president to address its findings.
Novo Nordisk to slash Wegovy, Ozempic list prices
Board certified rheumatologist Dr. Mahsa Tehrani discusses Novo Nordisk’s decision to dramatically cut the U.S. list prices for its popular diabetes and weight-loss drugs Ozempic and Wegovy on ‘America Reports.’
NEWYou can now listen to Fox News articles!
Millions of Medicare beneficiaries struggling with obesity could soon see the cost of weight-loss drugs plummet, as a new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors.
Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month, The Associated Press reported.
The covered medications include drugmaker Eli Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets, all of which have been FDA-approved for weight loss, according to the report.
OZEMPIC USERS MAY BE MAKING A MAJOR WEIGHT-LOSS MISTAKE, NEW STUDY SUGGESTS
The temporary program is set to run until the end of 2027.
This is the first time GLP-1s (glucagon-like peptide-1 receptor agonists) will be covered by insurance when used solely for weight loss.
A new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors. (iStock)
Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide). However, both manufacturers offered some cash-pay options that significantly reduced those prices for eligible patients.
GLP-1 WEIGHT LOSS DRUGS ARE RESHAPING THE BRIDAL INDUSTRY AS SHOPS RUSH ORDERS AND REQUIRE NEW WAIVERS
There are some parameters surrounding the coverage — older adults must have had a body mass index (BMI) of 35 or higher when they started GLP-1 therapy, or a BMI of 27 or higher alongside another health condition, such as a past heart attack or stroke or prediabetes.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Those who already have insurance coverage for other diseases, such as diabetes and sleep apnea, are not eligible for the program.
Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month. (iStock)
There are more than 70 million Americans currently enrolled in Medicare, 10 million of whom are overweight or obese, according to Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“For many older Americans living with obesity, this is a moment they and their families have been waiting for,” Jamey Millar, Novo Nordisk’s executive vice president of U.S. operations, said in a press release.
“The Medicare GLP-1 Bridge program offers a new, affordable path to an FDA-approved treatment that was previously not covered.”
CLICK HERE FOR MORE HEALTH STORIES
Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said he hopes the program can help his agency collect data to potentially work toward longer-term coverage, while providing immediate relief to cash-strapped older Americans, AP reported.
“The sheer cost of these medications is a huge barrier to access,” he said in a call with reporters. “That ends today.”
Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide). (iStock)
Oz told reporters that CMS plans to “carefully track participation and outcomes” to see whether an extension of the Bridge program or another solution is the best way to move forward. He told AP a federal law permanently allowing the coverage is “not essential right now” but something “for Congress to debate amongst themselves.”
“We can’t decide what’s going to happen long term with Bridge until we see some of the data,” he said, adding that there are ongoing talks with drug companies to lower costs.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
One potential concern is that older patients tend to have more adverse effects to medication in general , according to Dr. Micah Eimer, a clinical assistant professor of cardiology at the Northwestern University Feinberg School of Medicine.
“Specifically, in our research, older patients on blood pressure medications were more likely to experience hypotensive side effects, such as fainting and dizziness, after starting a GLP-1,” he said in a statement.
The Associated Press contributed to this report.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
Federal health officials are attempting to track down the source of a microscopic parasite that triggers prolonged gastrointestinal illness, as domestic cases begin to climb for the summer season.
The Centers for Disease Control and Prevention had confirmed 145 cases of cyclosporiasis across 17 states as of mid-June 2026, all linked to infections acquired in the U.S.
The culprit is Cyclospora, a microscopic parasite known to cause cyclosporiasis.
DEADLY ‘FOX TAPEWORM’ LINKED TO LETHAL DISEASE DETECTED IN WEST COAST WILDLIFE
The hallmark symptom of the infection is watery, often “explosive” diarrhea that can last for weeks or even months if left untreated, the CDC says.
There is currently no evidence of a single, multistate Cyclospora outbreak linking all cases. (AP Photo/Jeff Amy, File)
Other symptoms include severe abdominal cramping, bloating, nausea, fatigue and significant weight loss.
The official outbreak season for the parasite runs from May 1 through Aug. 31, a window where warmer temperatures historically coincide with a spike in infections, according to the CDC.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Cases have cropped up in states ranging from Texas to Alaska. New York has been hit the hardest so far, reporting between 31 and 80 cases, followed by Texas and Illinois, which have each reported between 11 and 30 cases.
CLICK HERE FOR MORE HEALTH STORIES
While the infection can sometimes clear up on its own, it frequently requires antibiotics. Out of the 145 confirmed cases, 20 patients have required hospitalization, per the CDC.
While the infection can sometimes clear up on its own, it frequently requires antibiotics. (iStock)
No deaths have yet been reported. Patients range from 5 to 86 years old, though the median age is 42, and women make up 61% of the reported cases, data shows.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The CDC, alongside the Food and Drug Administration and state health officials, is actively investigating several multi-state clusters, but they have yet to find a cause behind the spread.
Officials urge patients with symptoms to seek help from a medical professional. (iStock)
“There is currently no evidence of a single, multistate Cyclospora outbreak linking all cases,” the CDC noted in its surveillance report.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The CDC advises anyone experiencing symptoms of cyclosporiasis to contact a healthcare provider for testing and treatment.
-
Politics4 minutes agoWATCH: Controversial SCOTUS decision strikes a divide among lawmakers
-
Health11 minutes agoBig Medicare change slashes weight-loss drug costs for eligible seniors
-
Sports14 minutes agoVAR denies Croatia’s game-tying goal as Cristiano Ronaldo leads Portugal to Round of 16
-
Technology19 minutes agoNew sodium-ion battery could reshape grid storage
-
Business26 minutes agoHome insurer surcharges for wildfires is legal, judge rules
-
Entertainment29 minutes agoCalifornia designates Bruce Lee Day, first such honor for a Chinese American
-
Lifestyle34 minutes agoAhead of America’s 250th birthday, a photographer finds unity in tarnished state quarters
-
Politics41 minutes agoFacing setbacks and resistance, Trump presses bid to reshape elections on multiple fronts
